Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Deciphering tph cells as prognostic drivers of angioimmunoblastic T-cell lymphoma

Haiyan Yang, Kaiyang Ding, Cong Li, Weihao Zhuang, Yangjie Ru, Jieyu Xu, Xinchen Wang, XI Chen, Xiaowu Dong, Tao Lei, Jialiang Lu

Blood (2025) 146 (Supplement 1): 5305.

https://doi.org/10.1182/blood-2025-5305

Published: 2025

Journal Articles

Health-related quality of life in Chinese multiple myeloma patients treated with daratumumab-based regimens in real world: Exploratory analysis of the MMY4032

Luqun Wang, Wei Yang, Yafei Wang, Ting Niu, Rong Fu, Yuping Zhong, Wenbin Qian, Kaiyang Ding, Kai Sun, Hong Liu, Baijun Fang, Hui Liu, Yanhui Li, Yishen Yang, Jianmin Zhuo, Xi Chen, Jin Lu

Blood (2025) 146 (Supplement 1): 7529.

https://doi.org/10.1182/blood-2025-7529

Published: 2025

Journal Articles

Efficacy and safety of zanubrutinib combined with g-CVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisone) for first-line treatment of follicular lymphoma

Jieyu Xu, Haifeng Yu, Cong Li, XI Chen, Shuiyun Han, Shuailing Peng, Tao Lei, Haiyan Yang

Blood (2025) 146 (Supplement 1): 7103.

https://doi.org/10.1182/blood-2025-7103

Published: 2025

Journal Articles

BIRC5 inhibition as a novel approach to target RAS mutant and drug-resistant multiple myeloma

Jeremiah Pfitzer, Joachim Petit, Harish Kumar, Razan Waliagha, Xi Chen, Adam Keeton, Yulia Maxuitenko, Zachary Davis, Kelli Gyotoku, Linda Baughn, Aimee Merino, Shaji Kumar, Gary Piazza, Taraswi Ghosh, Brian Van Ness, Amit Mitra

Blood (2025) 146 (Supplement 1): 5705.

https://doi.org/10.1182/blood-2025-5705

Published: 2025

Journal Articles

Glofitamab-based combinatorial therapy demonstrates high efficacy in primary refractory and early relapsed DLBCL: Real-world evidence of durable responses and immune modulation in high-risk subgroups

Kexing Ren, Liqun Zou, Beibei Yang, Ming Jiang, Xi Chen, Li Xie, Chunli Yang, Tao Hai, Mo Chen, Tian Fang, Yafei Pi

Blood (2025) 146 (Supplement 1): 7255.

https://doi.org/10.1182/blood-2025-7255

Published: 2025

Journal Articles

Real-world evidence of improved survival with pola-based regimen in newly diagnosed DLBCL patients with extranodal involvement

Xi Chen, Kexing Ren, Ming Jiang, Liqun Zou

Blood (2025) 146 (Supplement 1): 5472.

https://doi.org/10.1182/blood-2025-5472

Published: 2025

Journal Articles

The whole brain radiotherapy is a safe and effective backbone in primary central nervous system lymphoma: A 23-year real-world experience

Haiyan Yang, Cong Li, Tao Lei, XI Chen, Haifeng Yu

Blood (2025) 146 (Supplement 1): 2752.

https://doi.org/10.1182/blood-2025-2752

Published: 2025

Journal Articles

Development of a NO probe cell imaging method based on CD58 expression in diffuse large B-cell lymphoma and as a tool to predict CAR-T efficacy

Xiyue Xu, Huan Zhou, Jialiang Lu, XI Chen, Yangjie Ru, Weihao Zhuang, Cong Li, Jieyu Xu, Qian Chen, Yiqun Chu, Xiaowu Dong, Tao Lei, Jinxin Che, Haiyan Yang

Blood (2025) 146 (Supplement 1): 2551.

https://doi.org/10.1182/blood-2025-2551

Published: 2025

Journal Articles

Polatuzumab vedotin plus R-CHP demonstrates high efficacy with manageable toxicity in treatment-Naïve dual-expressor DLBCL (DEL): Real-world analysis with focus on elderly high-risk patients

Kexing Ren, Liqun Zou, Xi Chen, Ming Jiang, Tian Fang, Li Xie, Beibei Yang, Tao Hai, Chunli Yang, Mo Chen, Yafei Pi

Blood (2025) 146 (Supplement 1): 3698.

https://doi.org/10.1182/blood-2025-3698

Published: 2025

Journal Articles

Novel gsdmd agonist dmb induces synergistic pyroptosis and apoptosis in diffuse large B-cell lymphoma

Shihui Mao, Fangrong Shi, Jieyu Xu, XI Chen, Jialiang Lu, Xiaowu Dong, Haiyan Yang

Blood (2025) 146 (Supplement 1): 6822.

https://doi.org/10.1182/blood-2025-6822

Published: 2025

Journal Articles

Upregulation of extracellular matrix remodeling gene set drives progression and poor prognosis in angioimmunoblastic T-cell lymphoma.

Jieyu Xu, Weihao Zhuang, Yangjie Ru, Cong Li, XI Chen, Yiqun Chu, Fangrong Shi, Haifeng Yu, Huilin Peng, Jinxin Che, Tao Lei, Jialiang Lu, Haiyan Yang

Blood (2025) 146 (Supplement 1): 1874.

https://doi.org/10.1182/blood-2025-1874

Published: 2025

Journal Articles

PK/PD Study of Zanubrutinib in Primary Chronic Lymphocytic Leukemia Patients

Zhenshu Xu, Ping Weng, Shujuan Xu, Yun Huang, Guangyao Guo, Zezhong Yu, Jie Lin, Liping Liu, Renyao Pan, Changgui Wang, Xi Chen, Yumenglin Bai

Blood (2024) 144 (Supplement 1): 5840.

https://doi.org/10.1182/blood-2024-200091

Published: 2024

Journal Articles

Efficacy and Safety of Carfilzomib-Based Regiments for the Treatment of Relapsed or Refractory Multiple Myeloma: Single-Center Real-Word Data

Weiwei Zhao, Juan Liu, Liyan Chen, Lianjie Wang, Yanming Xue, Yaoyao Tian, Yao Liu, Xiushuai Dong, Yuying Chang, Xi Chen, Liqian Yu, Xiaomin Zhang, Yinglan Jin, Yan Song, Biqing Han, Dandan Yao, Wei Wang

Blood (2024) 144 (Supplement 1): 7024.

https://doi.org/10.1182/blood-2024-204383

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory (R/R) Central Nervous System Lymphoma or Treatment-Naïve (TN) Central Nervous System Lymphoma, Results from the Phase Ib Combination Part of HZ-a-018-102 Study

Wenbin Li, Zhuang Kang, Feng Chen, Shenglan Li, Xi Chen, Xianggui Yuan, Haiyan Yang, Wenbin Qian, Miao Hu, Yanping Zhang, Xinglu Zhou

Blood (2024) 144 (Supplement 1): 6482.

https://doi.org/10.1182/blood-2024-201166

Published: 2024

Journal Articles

MBS303, a Novel 2:1 CD20×CD3 Bispecific Antibody, Demonstrated a Favorable Safety and Potent Antitumor Activity in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma: Preliminary Results from a Phase Ⅰ, Dose-Escalation Trial

Yuqin Song, Haiyan Yang, Youchao Jia, Lixia Sheng, Lijuan Deng, Xi Chen, Yongjing Tang, Xifang Liu, Sijun Liu, Min Wei, Feng Li

Blood (2024) 144 (Supplement 1): 6481.

https://doi.org/10.1182/blood-2024-199342

Published: 2024

Journal Articles

Spatial Multi-Omics Treatment Paradigms in a Phase II Clinical Study of Early Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Meijuan Wu, Xi Chen, Jialiang Lu, Weihao Zhuang, Chang He, Cong Li, Haifeng Yu, Tao Lei, Xiaowu Dong, Jianpeng Sheng, Haiyan Yang

Blood (2024) 144 (Supplement 1): 2996.

https://doi.org/10.1182/blood-2024-203388

Published: 2024

Journal Articles

Preclinical Development of a Novel Pan-RAS Inhibitor Against Relapsed/Refractory Multiple Myeloma

Jeremiah C. Pfitzer, Razan Waliagha, Linda B. Baughn, Adam B. Keeton, Xi Chen, Yulia Maxuitenko, Shaji Kumar, Brian Van Ness, Gary Piazza, Amit K Mitra

Blood (2024) 144 (Supplement 1): 3263.

https://doi.org/10.1182/blood-2024-207683

Published: 2024

Journal Articles

Effectiveness and Safety of Polatuzumab Vedotin-Based Therapy for Diffuse Large B-Cell Lymphoma: Real-Life Experience from China

Xi Chen, Haifeng Yu, Cong Li, Jieyu Xu, Tao Lei, Shuiyun Han, Shuailing Peng, Haiyan Yang

Blood (2024) 144 (Supplement 1): 7782.

https://doi.org/10.1182/blood-2024-207832

Published: 2024

Journal Articles

Novel Combination Regimen Brentuximab Vedotin-Bege Achieves Remarkable Efficacy in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Xi Chen, Huilin Peng, Haifeng Yu, Cong Li, Tao Lei, Shuiyun Han, Shuailing Peng, Haiyan Yang

Blood (2024) 144 (Supplement 1): 6364.

https://doi.org/10.1182/blood-2024-207627

Published: 2024

Journal Articles

Real-World Clinical Outcomes of Daratumumab-Based Regimens in Chinese Patients with Multiple Myeloma By Cytogenetic Risk: A Subgroup Analysis of the MMY4032 Study

Luqun Wang, Wei Yang, Ting Niu, Yafei Wang, Rong Fu, Yuping Zhong, Kaiyang Ding, Kai Sun, Baijun Fang, Hong Liu, Wenbin Qian, Hui Liu, Yanhui Li, Yishen Yang, Jianmin Zhuo, Xi Chen, Canchan Cui, Jin Lu

Blood (2024) 144 (Supplement 1): 7874.

https://doi.org/10.1182/blood-2024-201134

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Deciphering tph cells as prognostic drivers of angioimmunoblastic T-cell lymphoma

Health-related quality of life in Chinese multiple myeloma patients treated with daratumumab-based regimens in real world: Exploratory analysis of the MMY4032

Efficacy and safety of zanubrutinib combined with g-CVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisone) for first-line treatment of follicular lymphoma

BIRC5 inhibition as a novel approach to target RAS mutant and drug-resistant multiple myeloma

Glofitamab-based combinatorial therapy demonstrates high efficacy in primary refractory and early relapsed DLBCL: Real-world evidence of durable responses and immune modulation in high-risk subgroups

Real-world evidence of improved survival with pola-based regimen in newly diagnosed DLBCL patients with extranodal involvement

The whole brain radiotherapy is a safe and effective backbone in primary central nervous system lymphoma: A 23-year real-world experience

Development of a NO probe cell imaging method based on CD58 expression in diffuse large B-cell lymphoma and as a tool to predict CAR-T efficacy

Polatuzumab vedotin plus R-CHP demonstrates high efficacy with manageable toxicity in treatment-Naïve dual-expressor DLBCL (DEL): Real-world analysis with focus on elderly high-risk patients

Novel gsdmd agonist dmb induces synergistic pyroptosis and apoptosis in diffuse large B-cell lymphoma

Upregulation of extracellular matrix remodeling gene set drives progression and poor prognosis in angioimmunoblastic T-cell lymphoma.

PK/PD Study of Zanubrutinib in Primary Chronic Lymphocytic Leukemia Patients

Efficacy and Safety of Carfilzomib-Based Regiments for the Treatment of Relapsed or Refractory Multiple Myeloma: Single-Center Real-Word Data

Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory (R/R) Central Nervous System Lymphoma or Treatment-Naïve (TN) Central Nervous System Lymphoma, Results from the Phase Ib Combination Part of HZ-a-018-102 Study

MBS303, a Novel 2:1 CD20×CD3 Bispecific Antibody, Demonstrated a Favorable Safety and Potent Antitumor Activity in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma: Preliminary Results from a Phase Ⅰ, Dose-Escalation Trial

Spatial Multi-Omics Treatment Paradigms in a Phase II Clinical Study of Early Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Preclinical Development of a Novel Pan-RAS Inhibitor Against Relapsed/Refractory Multiple Myeloma

Effectiveness and Safety of Polatuzumab Vedotin-Based Therapy for Diffuse Large B-Cell Lymphoma: Real-Life Experience from China

Novel Combination Regimen Brentuximab Vedotin-Bege Achieves Remarkable Efficacy in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Real-World Clinical Outcomes of Daratumumab-Based Regimens in Chinese Patients with Multiple Myeloma By Cytogenetic Risk: A Subgroup Analysis of the MMY4032 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only